Post-Market Study of The Tripod-Fix Vertebral Body Augmentation System in Osteoporotic Vertebral Compression Fractures
- Conditions
- Osteoporotic Vertebral Compression Fractures
- Interventions
- Device: Tripod-Fix Vertebral Body Augmentation System (Tripod-Fix)
- Registration Number
- NCT06270173
- Lead Sponsor
- Wiltrom Co., Ltd.
- Brief Summary
The objective of this Post-Market Clinical Follow-Up Study is to evaluate the safety and performance of the Tripod-Fix in the treatment of vertebral compression fractures (VCF) resulting from osteoporosis.
- Detailed Description
This study is a prospective, multicenter, open-label, single-arm, PMCF study. The sample size for this study will be 50 patients. Eligible patients will be treated with Tripod-Fix on Day 0 and will be followed for a total of 12 months.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 53
-
Provision of signed and dated informed consent form prior to any study procedures
-
Stated willingness to comply with all study procedures and availability for the duration of the study
-
Skeletally mature males and females
-
1 painful VCF which meets all of the following criteria:
- Fracture due to diagnosed or presumed underlying osteoporosis (T-score < -2.5 points)
- VCF between T6 and L5
- VCF shows loss of height in the anterior, mid or posterior third of the vertebral body from an estimated pre-fracture configuration, but no more than 50% based on X-ray, CT or MRI at baseline.
- The Index fracture is acute or persistent (not healed), as demonstrated by MRI (or bone scan if the patient is contraindicated for MRI).
-
Investigator believes target vertebral body is suitable for Tripod-Fix procedure (e.g., appropriate pedicle diameter) assessed on radiography preoperative.
Tripod-Fix is not indicated for any other application other than that for which it is designed. contraindications for Tripod-Fix include, but are not limited to: .
- Patient presenting a loss of vertebral height >50% compared to estimated pre-fracture height
- Sclerotic fracture
- Patient with a prior history of intolerance or of allergic reaction to titanium and/or one of the components of the PMMA cement
- Patient suffering from irreversible coagulopathy or undergoing anticoagulant treatment at the moment of surgery or at least 8 days prior to inclusion
- Active infection (systemic or in the target vertebra)
- Patient suffering from a severe or uncontrolled systemic disease
- Patient presenting a pathological fracture with the presence of a mass within the spinal canal
- Patient presenting neurological damage caused by vertebral fracture
- Patient pregnant or likely to be so or breastfeeding
- Patient vertebral anatomy not compatible with the size of the implant or instrumentation
- Fracture geometry making the insertion of the implant impossible
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Intervention Tripod-Fix Vertebral Body Augmentation System (Tripod-Fix) Tripod-Fix will be used to treat osteoporotic vertebral compression fractures.
- Primary Outcome Measures
Name Time Method Proportion of participants with study success 12 months post-procedure Study success is defined as follows:
1. The reduction of Visual Analogue Scale (VAS) score \> 20 mm at the 12 month follow up visit compared to baseline as measured by the 100-mm VAS measurement, AND
2. Maintenance or improvement in function at the 12 month follow up visit compared to baseline as measured by the 100-point Oswestry Disability Index (ODI) AND,
3. Absence of device-related serious adverse events.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (4)
Klinikum Friedrichshafen
🇩🇪Friedrichshafen, Baden-Württemberg, Germany
University Hospital Mannheim
🇩🇪Mannheim, Baden-Württemberg, Germany
Johann Wolfgang Goethe University Frankfurt/Main
🇩🇪Frankfurt am Main, Hesse, Germany
Krankenaus Mechernich
🇩🇪Mechernich, North-Rhine-Westphalia, Germany